Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune diseases. The company's mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm. Landos has a portfolio of novel targets anchoring two libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space. The company is currently focused on advancing the clinical development of NX-13 in UC. Landos initiated its NEXUS Phase 2 proof-of-concept trial in April 2023 and expects to report topline results by the fourth quarter of 2024.